Aurora B kinase expression in laryngeal squamous cell carcinoma and its prognostic implications

Abstract

International audienceAims: To investigate the clinical and prognostic significance of Aurora B in laryngeal squamous cell carcinomas (LSCC). Methods and results: Aurora B protein expression was analyzed in a series of 259 LSCC. In addition, the expression of the proliferation index (Ki67) and other proteins involved in cell cycle control, such as Aurora A, survivin and p53 was also determined. Aurora B was highly expressed in 55.4% of LSCC. High Aurora B expression levels were correlated with tumour recurrence (P = 0.01), dead of disease (P = 0.05), and decreased disease-free survival (P = 0.013) and overall survival (P = 0.04). Survivin expression was neither associated with clinicopathological characteristics nor with survival. However, survivin expression in the nucleus paralleled Aurora B expression (P = 0.014). Aurora A expression was significantly associated with increased tumour grade (P = 0.008). Multivariate analysis indicated that Aurora B was an independent predictor for LSCC-specific disease-free survival (hazard ratio [HR], 2.10; 95% confidence interval [95% CI], 1.25-3.52 [P = 0.005]) and overall survival (HR, 1.91; 95% CI, 1.01-3.34 [P = 0.023]). Conclusions: Aurora B may be a novel prognostic biomarker for LSCC and a potential therapeutic target in this type of tumour

High proliferation index, as determined by immunohistochemical expression of Aurora kinase B and geminin, indicates poor prognosis in neuroblastomas

“…Univariable analysis showed high AURKB and GMNN PI to be associated with a significantly worse prognosis in terms of OS and EFS, in agreement with publicly available NB gene expression array data (R2: microarray analysis and visualization platform (http://r2.amc.nl)). Our data are also in line with studies that showed an association between increased immunohistochemical expression of AURKB and shorter survival in head and neck [31], laryngeal [32], lung [33], hepatocellular [34], biliary tract [35], endometrial [36], and ovarian cancer [37]. Similarly, our results are consistent with association between high GMNN level and shorter survival in breast [38], penile [39], renal cell [40], and other cancers, reviewed by Kapoor [41] and Petropoulou et al [20].…”

Survivin and laryngeal carcinoma prognosis: nuclear localization and expression of splice variants

“…Very recently, García‐Fernández et al. 23 determined survivin, Aurora B, Aurora A and p53 expressions in a large series of 259 LSCCs. Survivin expression was assessable in 234 cases: 100% of the cases showed cytoplasmic survivin expression and 45% a nuclear‐cytoplasmic pattern.…”

The radiosensitizing effect of the aurora kinase inhibitors, ENMD‐2076, on canine mast cell tumours in vitro

“…) of aurora‐A and aurora‐B were clearly detected by RT‐PCR and western blots. In humans, over‐expression of aurora‐A and/or aurora‐B has been suggested as prognostic markers in some types of malignant tumours . Quantification of the mRNA between malignant tumours, and investigating its relationship to the treatment response and/or prognosis would be a useful next step.…”